China Clinical Trial Management

As part of the NMPA’s ongoing regulatory evolution, the Chinese competent authority, formerly known as the CFDA, has released a draft list of new product types to be considered exempt from clinical trials as part of the registration process moving forward. Exempted Products will still need to submit a Clinical Evaluation Report (CER) but will save considerable time and money. Since its inception, the Clinical Trial Exemption List has been an important factor for foreign manufacturers considering entering the Chinese market as the Clinical Trials can be redundant, costly and time consuming. For a product type to be added to the Exemption List, the NMPA must see the device’s technology as mature with a proven history of safety and effectiveness or find that clinical trials with this type of product are not feasible.

Learn more about the newly drafted Clinical Trial Exemption List here.

Contact Asia Actual to see if our China Clinical Trial Management service is right for your business.